SCM
CASC

Segantii Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Segantii Capital Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-58,647
Closed -$243K – 368
2017
Q1 		$243K Buy
+58,647
New +$247K 0.04% 127

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Segantii Capital Management's CASC Position: Q2 2017 in Review

Segantii Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2017, closing a stake of 58,647 shares — an estimated $243K sold.

Segantii Capital Management first reported a position in CASC in Q1 2017 and held it in 1 quarter. The position peaked at $243K in Q1 2017. 76 funds tracked by Wall St. Rank hold CASC as of Q2 2017.

  • Segantii Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 58,647 Cascadian Therapeutics, Inc. shares in Q2 2017, an estimated $243K.
  • Segantii Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Cascadian Therapeutics, Inc. position peaked at $243K in Q1 2017.
  • 76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.